Suscripción a Biblioteca: Guest
Critical Reviews™ in Oncogenesis

Publicado 4 números por año

ISSN Imprimir: 0893-9675

ISSN En Línea: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Current Status of Radiosensitizing Agents for the Management of Rectal Cancer

Volumen 17, Edición 4, 2012, pp. 345-359
DOI: 10.1615/CritRevOncog.v17.i4.40
Get accessGet access

SINOPSIS

The management of locally advanced rectal cancer requires a multidisciplinary effort. Surgical resection remains the therapeutic cornerstone, but neoadjuvant chemoradiation clearly improves both surgical and long-term outcomes. Pathological complete response is a desirable outcome and has been associated with good long-term outcomes. This article provides an overview of the evolution and current role of radiosensitizing chemotherapy when given as part of neoadjuvant chemoradiation for locally advanced rectal cancer. 5-fluorouracil, given either as an infusion or orally as capecitabine, appears to have the most favorable balance of efficacy and tolerability at the present time. Oral administration without need for central IV access makes capecitabine an attractive option. Oxaliplatin and irinotecan have demonstrated increased toxicity without substantial associated improvement in outcomes. Both bevacizumab and cetuximab appear feasible when given with radiosensitizing chemotherapy, but no strong signal of improved efficacy has been demonstrated so far. There is currently a great need for new radiosensitizing agents and predictive biomarkers to help optimize the use of existing therapeutics. Increased topoisomerase I expression and increased EGFR gene copy number as possible predictors of response to irinotecan- and cetuximab-based chemoradiation, respectively, deserve further studies.

CITADO POR
  1. McDermott Niamh, Meunier Armelle, Lynch Thomas H., Hollywood Donal, Marignol Laure, Isogenic radiation resistant cell lines: Development and validation strategies, International Journal of Radiation Biology, 90, 2, 2014. Crossref

  2. Bergsland Emily K., Is More Not Better?, Hematology/Oncology Clinics of North America, 29, 1, 2015. Crossref

  3. Coveler Andrew L., Richard Patrick, Apisarnthanarax Smith, Chiorean E. Gabriela, Is There a Best Radiosensitizing Agent in the Treatment of Locally Advanced Rectal Cancer?, Current Colorectal Cancer Reports, 12, 4, 2016. Crossref

  4. Zhang Shijie, Wang Lei, Liu Hongchun, Zhao Guoqiang, Ming Liang, Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells, Diagnostic Pathology, 9, 1, 2014. Crossref

  5. Shan Wulin, Dai Chunyang, Zhang Huanhuan, Han Dan, Yi Qiyi, Xia Bairong, ACY1 Downregulation Enhances the Radiosensitivity of Cetuximab-Resistant Colorectal Cancer by Inactivating the Wnt/β-Catenin Signaling Pathway, Cancers, 14, 22, 2022. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain